1. Home
  2. COP vs VRTX Comparison

COP vs VRTX Comparison

Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COP
  • VRTX
  • Stock Information
  • Founded
  • COP 1917
  • VRTX 1989
  • Country
  • COP United States
  • VRTX United States
  • Employees
  • COP N/A
  • VRTX N/A
  • Industry
  • COP Integrated oil Companies
  • VRTX EDP Services
  • Sector
  • COP Energy
  • VRTX Technology
  • Exchange
  • COP Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • COP 119.9B
  • VRTX 115.6B
  • IPO Year
  • COP N/A
  • VRTX 1991
  • Fundamental
  • Price
  • COP $95.57
  • VRTX $470.43
  • Analyst Decision
  • COP Buy
  • VRTX Buy
  • Analyst Count
  • COP 18
  • VRTX 25
  • Target Price
  • COP $120.06
  • VRTX $508.91
  • AVG Volume (30 Days)
  • COP 8.9M
  • VRTX 1.3M
  • Earning Date
  • COP 08-07-2025
  • VRTX 08-04-2025
  • Dividend Yield
  • COP 3.27%
  • VRTX N/A
  • EPS Growth
  • COP N/A
  • VRTX N/A
  • EPS
  • COP 7.91
  • VRTX N/A
  • Revenue
  • COP $59,090,000,000.00
  • VRTX $11,099,700,000.00
  • Revenue This Year
  • COP $7.63
  • VRTX $10.48
  • Revenue Next Year
  • COP $1.76
  • VRTX $10.69
  • P/E Ratio
  • COP $12.08
  • VRTX N/A
  • Revenue Growth
  • COP 4.00
  • VRTX 8.98
  • 52 Week Low
  • COP $79.88
  • VRTX $377.85
  • 52 Week High
  • COP $118.40
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • COP 58.68
  • VRTX 60.14
  • Support Level
  • COP $93.20
  • VRTX $455.79
  • Resistance Level
  • COP $96.92
  • VRTX $484.56
  • Average True Range (ATR)
  • COP 2.28
  • VRTX 8.51
  • MACD
  • COP 0.32
  • VRTX 3.43
  • Stochastic Oscillator
  • COP 83.37
  • VRTX 68.83

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. In 2024, it produced 2.0 million barrels per day of oil and natural gas liquids and 3.4 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2024 were 7.8 billion barrels of oil equivalent.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: